Skip to content
Inciteful Med

Managing Your Care: Standard Treatments and the Specialist Team

Last updated:

Noonan syndrome requires a multidisciplinary care team including a cardiologist, endocrinologist, hematologist, and geneticist. Standard care involves regular heart monitoring, growth hormone therapy for short stature, and preventative bleeding workups before any surgeries or dental procedures.

Key Takeaways

  • • A coordinated team of specialists, typically led by a primary care doctor, is essential for managing Noonan syndrome across a patient's lifespan.
  • • Heart issues affect 80-90% of individuals with the condition, making regular EKG and echocardiogram screenings a top clinical priority.
  • • Growth hormone therapy is a highly effective standard treatment for addressing the short stature commonly associated with Noonan syndrome.
  • • A specialized bleeding workup should always be completed prior to surgeries or dental procedures to prevent clotting complications.
  • • MEK inhibitors like trametinib are emerging as specialized, off-label treatments for severe heart or lymphatic issues that do not respond to standard care.

Because Noonan syndrome (NS) affects many different parts of the body, managing it requires a “team approach” [1]. The standard of care involves regular monitoring by specialists to identify and treat symptoms early [2][3].

Your Core Care Team

A multidisciplinary team is essential for high-quality care. Your team should include:

  • Cardiologist: To monitor the heart and blood vessels [4].
  • Geneticist: To confirm the diagnosis and provide information on how the specific gene mutation may affect the long-term outlook [5][6].
  • Endocrinologist: To manage growth, hormone levels, and bone health [7].
  • Hematologist: To screen for and manage any bleeding or clotting issues [8].
  • Pediatrician/Primary Care Physician: To act as the “medical home” and coordinate between all specialists [5].

Cardiac Management: The Top Priority

Heart issues affect 80-90% of individuals with Noonan syndrome [9]. Standard care includes:

  • Baseline and Regular Screening: This involves an electrocardiogram (EKG) to check the heart’s electrical activity and an echocardiogram (ECHO) to look at the heart’s structure [4].
  • Monitoring for Progression: Conditions like pulmonary valve stenosis (narrowing of the heart valve) or hypertrophic cardiomyopathy (thickening of the heart muscle) can develop or change over time [4][10].
  • Treatment Options: For valve issues, a procedure called balloon valvuloplasty (using a small balloon to widen the valve) is common [11]. For severe muscle thickening that doesn’t respond to medication, surgery may be necessary [12].

Managing Growth and Development

Short stature is nearly universal in Noonan syndrome [13].

  • Growth Hormone Therapy: Treatment with recombinant human growth hormone (rhGH) is widely accepted and effective for improving growth velocity and adult height [14][15]. Starting this therapy before puberty typically leads to better results [16].
  • Developmental Support: Many children benefit from early intervention services, including physical, occupational, and speech therapy to address milestones and learning challenges [17][18].

Specialized and Emerging Treatments

  • Bleeding Workups: About half of people with NS have a “bleeding diathesis” (easy bruising or slow clotting) [8]. Before any surgery, including dental procedures, a specialized bleeding workup is necessary to prevent complications [8].
  • MEK Inhibitors (e.g., Trametinib): In severe cases where heart or lymphatic issues (like fluid buildup) do not respond to standard treatments, doctors may discuss “off-label” use of medications called MEK inhibitors [19][20]. These drugs target the overactive signaling pathway directly and have shown promise in reducing heart muscle thickening and severe lymphatic leaks, though they require very close monitoring [19][20].

Moving Forward with Your Team

While these emerging therapies offer hope for complex cases, the foundation of Noonan syndrome management remains consistent, coordinated care across your lifespan. Standard of care means having a proactive plan tailored to your specific genetic profile. If you feel your concerns are not being addressed or your specialists are not communicating, you may want to seek a center that specializes in RASopathies [5][6].

Return to Home Page

Frequently Asked Questions

Which doctors should be on a Noonan syndrome care team?
A comprehensive care team typically includes a cardiologist, geneticist, endocrinologist, hematologist, and a primary care physician or pediatrician who acts as the lead coordinator for all your specialists.
How often should someone with Noonan syndrome have their heart checked?
Because heart issues affect the vast majority of patients, regular cardiovascular screening is essential. This usually involves routine electrocardiograms (EKG) and echocardiograms (ECHO) to monitor for changes in heart structure or electrical activity.
Is growth hormone therapy used for Noonan syndrome?
Yes, treatment with recombinant human growth hormone is widely accepted and effective for improving growth and adult height. Starting this therapy before puberty generally provides the best results for addressing short stature.
Why do I need a bleeding workup before dental work or surgery?
About half of individuals with Noonan syndrome have a bleeding condition that causes easy bruising or slow clotting. A specialized bleeding workup by a hematologist helps identify these issues so your medical team can prevent excessive bleeding during procedures.
What are MEK inhibitors used for in Noonan syndrome?
MEK inhibitors, such as trametinib, are emerging off-label treatments for severe cases. Doctors may consider them when standard treatments fail to control severe heart muscle thickening or complex lymphatic fluid leaks.

Questions for Your Doctor

  • • Who is the 'lead' specialist coordinating my (or my child’s) overall care between cardiology, genetics, and endocrinology?
  • • How often should we have a baseline echocardiogram (ECHO) and EKG to monitor for heart changes?
  • • Does our specific genetic mutation (e.g., RAF1) mean we should be screened for heart issues more frequently?
  • • Before any upcoming dental work or surgery, can we get a referral for a 'bleeding workup' with a hematologist?
  • • If standard treatments for heart or lymphatic issues aren't working, what is your experience with 'off-label' options like MEK inhibitors?

Questions for You

  • • Do I feel like each of my specialists is 'talking to' the others to coordinate care?
  • • Have I noticed any symptoms like easy bruising, frequent nosebleeds, or leg swelling that I should report to the team?
  • • What are my priorities for treatment right now—is it growth, heart health, or something else?
  • • Do I have a clear plan for what to do if a new symptom appears or an existing one worsens?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    The RASopathies: Biology, genetics and therapeutic options.

    Longo JF, Carroll SL

    Advances in cancer research 2022; (153()):305-341 doi:10.1016/bs.acr.2021.07.007.

    PMID: 35101235
  2. 2

    Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment.

    Linglart L, Gelb BD

    American journal of medical genetics. Part C, Seminars in medical genetics 2020; (184(1)):73-80 doi:10.1002/ajmg.c.31765.

    PMID: 32022400
  3. 3

    RASopathy in Patients With Isolated Sagittal Synostosis.

    Davis AA, Zuccoli G, Haredy MM, et al.

    Global pediatric health 2019; (6()):2333794X19846774 doi:10.1177/2333794X19846774.

    PMID: 31192281
  4. 4

    Cardiac Manifestations of Noonan Syndrome.

    Karnik R, Geiger M

    Pediatric endocrinology reviews : PER 2019; (16(Suppl 2)):471-476 doi:10.17458/per.vol16.2019.kpg.manifestationsnoonan.

    PMID: 31115199
  5. 5

    A genotype-first approach to exploring Mendelian cardiovascular traits with clear external manifestations.

    Wenger BM, Patel N, Lui M, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(1)):94-102 doi:10.1038/s41436-020-00973-2.

    PMID: 32989268
  6. 6

    Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.

    Chinton J, Huckstadt V, Moresco A, et al.

    Archivos argentinos de pediatria 2019; (117(5)):330-337 doi:10.5546/aap.2019.eng.330.

    PMID: 31560489
  7. 7

    Case report: A de novo RASopathy-causing SHOC2 variant in a Chinese girl with noonan syndrome-like with loose anagen hair.

    Wang Q, Cheng S, Fu Y, Yuan H

    Frontiers in genetics 2022; (13()):1040124 doi:10.3389/fgene.2022.1040124.

    PMID: 36579329
  8. 8

    Bleeding phenotype and hemostatic evaluation by thrombin generation in children with Noonan syndrome: A prospective study.

    Barg AA, Yeshayahu Y, Avishai E, et al.

    Pediatric blood & cancer 2024; (71(2)):e30761 doi:10.1002/pbc.30761.

    PMID: 37974388
  9. 9

    Cardiac Phenotype and Gene Mutations in RASopathies.

    Faienza MF, Meliota G, Mentino D, et al.

    Genes 2024; (15(8)) doi:10.3390/genes15081015.

    PMID: 39202376
  10. 10

    Atypical cardiac defects in patients with RASopathies: Updated data on CARNET study.

    Calcagni G, Gagliostro G, Limongelli G, et al.

    Birth defects research 2020; (112(10)):725-731 doi:10.1002/bdr2.1670.

    PMID: 32558384
  11. 11

    Combined cardiac anomalies in Noonan syndrome: A case report.

    H S NS, S S, Patil R, et al.

    International journal of surgery case reports 2020; (72()):32-36 doi:10.1016/j.ijscr.2020.05.048.

    PMID: 32506025
  12. 12

    Long-term results of the modified Konno procedure in high-risk children with obstructive hypertrophic cardiomyopathy.

    Laredo M, Khraiche D, Raisky O, et al.

    The Journal of thoracic and cardiovascular surgery 2018; (156(6)):2285-2294.e2 doi:10.1016/j.jtcvs.2018.06.040.

    PMID: 30104063
  13. 13

    Noonan syndrome and Noonan-like syndrome with loose anagen hair: rare phenotypes may emerge during follow-up.

    Liu Z, Lai J, Song F

    Translational pediatrics 2024; (13(7)):1161-1168 doi:10.21037/tp-24-113.

    PMID: 39144424
  14. 14

    The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.

    Kucharska A, Witkowska-Sędek E, Erazmus M, et al.

    International journal of molecular sciences 2024; (25(18)) doi:10.3390/ijms251810169.

    PMID: 39337654
  15. 15

    Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study.

    Apperley LJ, Ramakrishnan R, Dharmaraj P, et al.

    International journal of endocrinology and metabolism 2020; (18(4)):e107292 doi:10.5812/ijem.107292.

    PMID: 33613679
  16. 16

    Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone Deficiency.

    Riaz M, Ibrahim MN, Rai VR, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024; (34(8)):932-935 doi:10.29271/jcpsp.2024.08.932.

    PMID: 39113512
  17. 17

    Juvenile xanthogranuloma in Noonan syndrome.

    Ali MM, Gilliam AE, Ruben BS, et al.

    American journal of medical genetics. Part A 2021; (185(10)):3048-3052 doi:10.1002/ajmg.a.62353.

    PMID: 34032360
  18. 18

    Neuropsychiatric phenotypes in children with Noonan syndrome.

    Naylor PE, Bruno JL, Shrestha SB, et al.

    Developmental medicine and child neurology 2023; (65(11)):1520-1529 doi:10.1111/dmcn.15627.

    PMID: 37130201
  19. 19

    Refractory Chylothorax and Ventricular Hypertrophy Treated with Trametinib in a Patient with Noonan Syndrome: 18-Month Follow-Up.

    Pascarella A, Limongelli G, De Falco A, et al.

    Children (Basel, Switzerland) 2024; (11(11)) doi:10.3390/children11111342.

    PMID: 39594917
  20. 20

    An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies.

    Yi JS, Perla S, Bennett AM

    Cardiovascular drugs and therapy 2023; (37(6)):1193-1204 doi:10.1007/s10557-022-07324-0.

    PMID: 35156148

This page provides educational information on managing Noonan syndrome and standard treatment protocols. Always consult your multidisciplinary healthcare team for personalized medical advice and screening recommendations.

Stay up to date

Get notified when new research about Noonan syndrome is published.

No spam. Unsubscribe anytime.